Exploratory Clinical Development World Europe - list of speakers 

Balaji Agoram, Ph.D. received his doctoral training in Chemical and Biological Engineering from the University of Colorado, Boulder in 2001. Since graduation, he has held positions of increasing scope within biotech and pharma companies of different sizes within clinical Pharmacology/DMPK/Pharmacometrics fields. He presently heads the...

Khusru Asadullah is Vice President and Head of Global Biomarker at Bayer HealthCare Pharmaceuticals. Before this he headed Target Discovery and Inflammation and Immunology research at Bayer Schering Pharma. He is a Professor of Medicine at the University Hospital Berlin. He graduated from the Medical School Charité, Berlin and the Harvard Business ...

Jiri Aubrecht is a Senior Director and Group Lead of Safety Biomarker Laboratories at Pfizer Worldwide Research and Development in Groton, CT. His research interests are the application of systems biology-based approaches for investigating toxic mechanisms and biomarker development with emphasis on qualification of novel biomarkers for risk...

Currently Head of Clinical Pharmacology in UCB, in the past 25 years I covered different roles in various pharmaceutical industries, including GlaxoSmithKline, Rottapharm, Zambon and Pharmacia-Upjohn. My recent experience was mainly dedicated to CNS drug development focusing of translational aspects, early clinical plans, dose...

Dr. Richard Buller is the Vice President of Translational Oncology in the Pfizer Oncology Business Unit. His group is responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates. Recent success is reflected by the approval of critoztinib for the treatment of ...

Rolf Burghaus started his scientific education at the Heinrich-Heine University of Düsseldorf in 1990 taking courses in mathematics and physics. He soon specialized in theoretical physics where he got his diploma in late 1995. He continued in the field and got his doctor degree in 1997 with a work on the diffusional growth of droplets in different ...

- I have an MSc in Mathematics from the University of Liege, Belgium, and a Masters in Biostatistics from the University of Hasselt, Belgium - I have been working as a statistician at Novartis since 2006, where I first supported phase III and IV trials. I am currently working in the Translational Sciences group where I support the design aspects...

Nigel Dallow is a Director of Clinical Statistics at GlaxoSmithKline supporting the respiratory area. Nigel has vast experience in working in drug development especially in the early phase area having worked at GSK for 17 years. Though his experiences, Nigel has a strong ethos in re-engineering phase II and is dedicated to exploring alternative...

Borje Darpo is board-certified in cardiology and internal medicine. He has over 12 years of pharmaceutical industry experience, including senior management positions in small, mid-sized and large pharma, as well as in a global CRO. He has led or has been responsible for projects in all phases of clinical development, including filing and approval...

Antoine Deslandes graduated in Pharmacy and received his Doctorate in Experimental and Clinical Pharmacology from the University of Paris. He joined Servier as preclinical studies manager in Psychiatry/Neurology. He then held different positions in Discovery DMPK at Parke-Davis and joined the eR&D programme at Pfizer Global R&D, as project leader...

Dr. Drijfhout holds a Ph.D. in Pharmacy and heads all early phase development and bio-analytical laboratory work for PRA. He was Chief Scientific Officer for Pharma Bio-Research prior to the company being acquired by PRA in mid 2006. He joined Pharma Bio-Research in 1996 and became a member of the Executive Board in 1999. Dr. Drijfhout has...

Dr. Eichenbaum joined Johnson & Johnson Pharmaceutical R&D, LLC (J&J) in 2002. He is a Preclinical Development Leader/Research Fellow in the department of Drug Safety Sciences. He serves on cross-functional compound development teams and is responsible for directing the Toxicology and DMPK research for early and late development programs...

David P. Elder has thirty four years experience within the Pharmaceutical Industry. He is currently a director at GlaxoSmithKline Pharmaceuticals. He obtained a part-time PhD from Edinburgh University in1992 investigating the crystal structure and solid-state chemistry of a series of pharmaceutical salts. He is a member of the BP-Committee PCY: ...

Aiden Flynn has worked for more than 18 years in the development and application statistics and modelling to drug discovery and development. After seven years as a Lecturer at University College London, he spent ten years at GlaxoSmithKline as Director of statistical support for biomarker studies across research and development. Currently, he is ...

Mark Graham is Senior Principal Scientist and Global Discipline Leader for Discovery Safety. He has published more than 30 peer reviewed papers and many presentations and lectures at scientific conferences. Currently a member of the ‘Committee on Toxicity (COT)’ which provides independent, expert advice on all aspects of chemical toxicity to...

Gerhard has a B.Sc. degree in Physics and Chemistry, and received his M.Sc. in Physics and Chemistry (1980) and Ph.D. in Organic Chemistry (1983) from the University of Marburg where he studied the generation of reactive molecules through flash vacuum pyrolysis. As a postdoc he worked with Prof. Michl in Utah, USA on multiple silicon bonds. In the ...

Mr. Heilbraun attended Tufts University in Boston, Massachusetts where he completed his Bachelor of Science degree in Biology with a focus on physiology. Jeff continued his studies at The American University in Washington D.C., receiving a fellowship and completing his Masters of Science in Health Promotion and Disease Management. He was employed...

Dr. Tycho Heimbach is an Associate Director at Novartis Institutes for BioMedical Research in East Hanover, NJ. In his current role, he chairs a global team which reviews and makes recommendations for formulation and PK/PD strategies for all disease areas within the global DMPK function. He also serves as a representative on a global food-effect ...

I completed my first degree in Pharmacy at the University of Manchester followed by a year working in community Pharmacy before studying for my PhD at the University of Nottingham. My PhD started to develop my core research interests of biopharmaceutics and Drug Delivery. I then spent two years working for Glaxo within a Discovery drug metabolism...

Walter Janssens obtained a PhD at the University of Antwerp and later did research at the University of Leuven. Then he became research scientist in pharmaceutical industry (Janssen Pharmaceutica) with main emphasis on cardiovascular and gastrointestinal physiology and pharmacology. From 2002 until May 2006 he worked on toxicological aspects of...

Dr. Kinter is currently Senior Director: Regulatory Toxicology, and Head: Toxicological Operations, Safety Assessment (US) at AstraZeneca Pharmaceuticals in Wilmington, PA., and manages preclinical safety programs conducted in support of AstraZeneca’s pharmaceutical clinical development activities in the US. Dr. Kinter has been engaged in...

Professor Graham Lappin received his BSc in Biochemistry (1981) and PhD (1984) from the University of Westminster (London UK). Following this he spent two years at the University of Glasgow researching into the anabolism of terpenoids in plant species. Following a period developing analytical methods for mass spectrometry, Graham joined ICI in...

Currently Dr. Gereon Lauer is Senior Group Leader at the Biomarker Development department in Nycomed: a Takeda company. His group is responsible for implementation of biomarker strategies into the development process of drug development projects from pro-clinical to late stage clinical phase III and life cycle development. In addition his group...

Thierry Lavé is Head of Modeling and Simulation, Non Clinical Safety, Hoffmann-La Roche. He received his degree in Pharmacy (1987) and Ph.D. (1992) from the Strasbourg University, France. Thierry has also 5 year of experience working as Internist at the University Hospital in Strasbourg and holds a degree in applied statistics for clinical...

Dr. Michael Merz is a clinical pharmacologist by training, with a focus on drug safety testing during the past couple of years. He worked as phase 1 investigator and Head of Phase 1 clinic for Quintiles in Freiburg, Germany, from 1993 to 1997 and joined Novartis Pharma in Basel, Switzerland, in 1998. At Novartis, he assumed responsibility as Head...

Robert Miller is the Chief Consultancy Officer and product development consultant for Aptiv Solutions. Dr Miller provides medical input into the strategy and design of development programmes in multiple indications (including those in inflammation, ischaemia-reperfusion, cardiovascular, respiratory, and oncological indications). Dr Miller...

Malcolm Mitchell is a graduate of Newcastle Medical School, following a decade in the NHS , he joined the pharmaceutical industry over 25 years ago, with positions in Pfizer, NAPP and Lilly. He has been working in clinical pharmacology at Eli Lilly for the past 18 years. He has been involved in ongoing drug development for many aspects of...

Studied medicine at the University of the Witwatersrand, Johannesburg, [BSc Hons in Physiology and Medical Biochemistry (1988) and MBBCh (1990)]. Received specialist training in psychiatry at the University of Cape Town from 1993-1997 (FCPsych SA, 1996). Trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London...

2005 Board certification as Clinical Pharmacologist Professional Experience (incl. Memberships) 1992 - 1993 Internship (Internal Medicine) 1993 - 1995 Scientist, Clinical Pharmacology, University of Rostock 1995 - 2001 Scientist, Clinical Pharmacology, Schering AG, Berlin Fields of responsibility: - Clinical Pharmacology Lead responsible for...

David H. Salinger, PhD, is a Principal Scientist in the Quantitative Pharmacology group of the Department of Pharmacokinetics and Drug Metabolism at Amgen Inc. in Seattle, Washington. He received his PhD in Applied Mathematics at the University of Washington. He worked as a Research Scientist for the Department of Ocean and Fisheries Sciences at ...

Jochen Theis is the founder and principle consultant of InHeCon, an integrated healthcare consultancy serving clients in the pharma/biotech, diagnostics, and venture capital industries. InHeCon focuses on modern, rational, and decision focussed research, development, and commercialisation of medicines and diagnostics through integration of...

Piet van der Graaf qualified as pharmacist at the University of Groningen (The Netherlands) in 1990 and obtained a Ph.D. in Clinical Medicine at King’s College London (UK) under supervision of Nobel laureate Sir James Black for his work on quantitative pharmacological characterisation of 1-adrenoceptors. He subsequently worked as a Post-Doc at...

Roche Genentech R&D is driven by two autonomous R&D centers gRED, Genentech & pRED, Roche Pharma Research & Exploratory Development. Andreas Wallnoefer is the Global Head of pRED Development and is a member of the pRED Leadership Team. He is also a core member of both the Exploratory (ESPC) and the Late stage (LSPC) Strategic Portfolio...

Joined Glaxo Group Research in 1987 in Department of Biochemical Pharmacology as a Bioanalyst. Through 2 mergers, firstly with Wellcome and then with SmithKline Beecham and have been involved in the area of AMS since 1997, within departments of Drug Metabolism. Acted as a "champion" of AMS in GlaxoWellcome and GSK, and since 2004 charged with...